赛他发定 Centanafadine HCl

大冢制药有限公司及其美国子公司大冢制药开发和商业化有限公司今天宣布了两项为期6周的3期临床试验的积极成果，这些试验评估了疗效，安全性，centanafadine治疗青少年和注意缺陷多动障碍（ADHD）的耐受性和耐受性。

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor..

Centanafadine是一流的去甲肾上腺素，多巴胺和5-羟色胺再摄取抑制剂。。

The first trial (NCT05257265) was a pivotal Phase 3, randomized, double-blind, three-arm, fixed-dose trial to evaluate the efficacy, safety, and tolerability of centanafadine for adolescents with ADHD from the ages of 13 to 17 years.2

第一项试验（NCT05257265）是一项关键的3期，随机，双盲，三臂，固定剂量试验，用于评估centanafadine对13至17岁ADHD青少年的疗效，安全性和耐受性